8 news items
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
VIR
29 May 24
the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
VIR
29 May 24
critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
VIR
23 May 24
the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural
9hblllft0vcl39b2d1jdlzbnsghbl5juszp h1wwp158sfytptmcmg9rx
VIR
11 Apr 24
system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting
nxzujy8nftf4mq38 dxzfgo81v6edgqfkmqodh0vld627oo
ANTX
VBIV
VIR
22 Mar 24
of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances
e0n8lvb1m25syg2dz0fo2v
VIR
5 Mar 24
critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta
- Prev
- 1
- Next